BTG granted Ariel exclusive, worldwide rights to develop and commercialize AP-1531 and a chemical library of PTGER4 antagonist ligands

BTG plc

U.K. / Mid-Cap Biopharma ($1-$50 billion)

$1,056.9m on 09/23/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ariel Pharmaceuticals Inc.

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!; This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced